Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883173 | PMC |
http://dx.doi.org/10.1016/j.clinsp.2022.100161 | DOI Listing |
Purpose: To report an incidence of procedure-related complications in preterm infants with retinopathy of prematurity (ROP) treated with intravitreal anti-VEGFs injection in both eyes on the same day.
Design: Retrospective, multicenter case series.
Subjects: Preterm infants with ROP treated with anti-VEGF bilaterally on the same day.
JMIR Public Health Surveill
October 2024
Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
Graefes Arch Clin Exp Ophthalmol
September 2024
Asc Academics, Groningen, The Netherlands.
Objective: Age-related macular degeneration (AMD) is the main cause of severe vision loss globally. Neovascular AMD (nAMD) is an advanced stage of AMD treated with anti-vascular endothelial growth factors (anti-VEGFs). Although anti-VEGF treatment is effective, the frequent intravitreal injections place a burden on patients, (in)formal caregivers, and clinics.
View Article and Find Full Text PDFPaediatr Drugs
September 2024
Health Research Institute (INCLIVA), Clinic University Hospital of Valencia, Valencia, Spain.
Objective: The efficacy and safety of propranolol for retinopathy of prematurity (ROP) remain under debate. This network meta-analysis (NMA) focuses on whether a ranking may be established for different dose levels of propranolol as treatment of ROP in terms of stage progression as the primary outcome, with appearance of plus disease and need for anti-vascular endothelial growth factors (anti-VEGFs) or laser therapy as secondary endpoints.
Methods: Fourteen studies (10 randomised controlled trials, three single-arm trials and one retrospective observational study) of 474 patients treated with oral or ocular propranolol were retrieved from databases up to April 2024.
Clin Ophthalmol
August 2024
Eye Clinic, Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Purpose: Limited data is available on treatment satisfaction with the management of wet age-related macular degeneration (wAMD) among patients in Italy. In this cross-sectional real-world study, treatment satisfaction with anti-vascular endothelial growth factor (anti-VEGFs) was assessed in patients with wAMD in Italy.
Patients And Methods: This was a non-interventional, cross-sectional survey involving patients with wAMD receiving anti-VEGFs.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!